Drug Profile

Clopidogrel bisulfate - Daewoong Pharmaceutical

Alternative Names: DWC-202202

Latest Information Update: 13 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daewoong Pharmaceutical
Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Marketed Atherosclerosis; Myocardial infarction; Peripheral arterial disorders; Stroke; Thromboembolism

13 Oct 2025 Launched for Atherosclerosis in South Korea (PO), before October 2025
13 Oct 2025 Launched for Myocardial infarction in South Korea (PO), before October 2025
13 Oct 2025 Launched for Peripheral arterial disorders in South Korea (PO), before October 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com